Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LLYthis companyEli Lilly and Company	$1,396.78	46.58×	36.37×	14.81×	31.57×	-47.2%	83.0%	45.6%	31.7%	77.8%	30.2%	0.9%	1.6×	1.12×	37.34×	1.58×	0.6%	7	9.47	3	B
ABBVAbbVie Inc.	$290.57	96.41×	-123.96×	6.63×	26.61×	-55.6%	70.2%	32.8%	6.9%	-129.2%	13.0%	4.4%	-21.12×	3.62×	6.94×	0.67×	2.9%	7	2.9	1	C-
AMGNAmgen Inc.	$458.13	22.84×	20.34×	4.79×	13.11×	92.1%	70.8%	29.1%	21.0%	89.1%	13.2%	4.6%	6.31×	2.69×	3.88×	1.14×	2.9%	8	2.44	3	B+
JNJJohnson & Johnson	$276.93	18.82×	6.18×	5.35×	12.97×	7.8%	67.9%	27.2%	28.5%	32.9%	13.7%	3.9%	0.59×	0.69×	26.36×	1.03×	2.5%	7	5.49	3	B+
MRKMerck & Co., Inc.	$147.02	14.42×	5.01×	4.06×	10.59×	19.4%	72.0%	36.2%	28.1%	34.7%	18.3%	4.7%	0.96×	1.27×	17.31×	1.54×	3.1%	6	3.99	1	C-
PFEPfizer Inc.	$29.14	18.31×	1.64×	2.26×	12.38×	19.3%	74.3%	27.8%	12.4%	9.0%	10.0%	6.4%	0.78×	3.95×	6.52×	1.16×	6.9%	6	2.16	3	B
Peer median	—	18.82×	5.01×	4.79×	12.97×	19.3%	70.8%	29.1%	21.0%	32.9%	13.2%	4.6%	0.78×	2.69×	6.94×	1.14×	2.9%	7	2.9	3	—